Health Canada Issues Recall of Pharmascience Inc`s PMS-Galantamine ER 8mg Capsule
Health Canada Issues Recall of Pro Doc Ltd.`s Galantamine ER Capsule
Health Canada Issues Recall of Pharmascience`s PMS-Galantamine ER Capsule
The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s disease is six times higher than a decade ago, official figures have revealed.
Alzheimer's drug development is a difficult venture, as pharma knows all too well. The meds' troubling side effects and potential safety issues make marketing a risky game, with few companies grabbing a seat at the table. According to a recent analysis of postmarketing data, meds from Novartis ($NVS), Allergan ($AGN) and Japan's Eisai turned up more reports of potentially dangerous side effects than other products.